Trial · NCT02468232
Results by group154
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 154
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number of Participants Who Had CEC (Clinical Endpoint Committee) Confirmed Composite Endpoints | LCZ696 | Primary composite | 30 | Participants | |
| Number of Participants Who Had CEC (Clinical Endpoint Committee) Confirmed Composite Endpoints | Enalapril | Primary composite | 28 | Participants | |
| Number of Participants Who Had CEC (Clinical Endpoint Committee) Confirmed Composite Endpoints | LCZ696 (Core) OLE Epoch | Primary composite | 0 | Participants | |
| Number of Participants Who Had CEC (Clinical Endpoint Committee) Confirmed Composite Endpoints | Enalapril (Core) OLE Epoch | Primary composite | 0 | Participants | |
| Number of Participants Who Had CEC (Clinical Endpoint Committee) Confirmed Composite Endpoints | LCZ696 | Cardiovascular (CV) Death | 13 | Participants | |
| Number of Participants Who Had CEC (Clinical Endpoint Committee) Confirmed Composite Endpoints | Enalapril | Cardiovascular (CV) Death | 11 | Participants | |
| Number of Participants Who Had CEC (Clinical Endpoint Committee) Confirmed Composite Endpoints | LCZ696 (Core) OLE Epoch | Cardiovascular (CV) Death | 0 | Participants | |
| Number of Participants Who Had CEC (Clinical Endpoint Committee) Confirmed Composite Endpoints | Enalapril (Core) OLE Epoch | Cardiovascular (CV) Death | 0 | Participants | |
| Number of Participants Who Had CEC (Clinical Endpoint Committee) Confirmed Composite Endpoints | LCZ696 | 1st heart failure (HF) Hospitalization | 25 | Participants | |
| Number of Participants Who Had CEC (Clinical Endpoint Committee) Confirmed Composite Endpoints | Enalapril | 1st heart failure (HF) Hospitalization | 20 | Participants | |
| Number of Participants Who Had CEC (Clinical Endpoint Committee) Confirmed Composite Endpoints | LCZ696 (Core) OLE Epoch | 1st heart failure (HF) Hospitalization | 0 | Participants | |
| Number of Participants Who Had CEC (Clinical Endpoint Committee) Confirmed Composite Endpoints | Enalapril (Core) OLE Epoch | 1st heart failure (HF) Hospitalization | 0 | Participants | |
| Exposure-adjusted Incident Rate (EAIR) of CEC Confirmed Composite Endpoints | LCZ696 | Primary composite | 11.376 | 95% Confidence Interval 7.676 to 16.240 | Events per 100 patient-years |
| Exposure-adjusted Incident Rate (EAIR) of CEC Confirmed Composite Endpoints | Enalapril | Primary composite | 10.497 | 95% Confidence Interval 6.975 to 15.170 | Events per 100 patient-years |
| Exposure-adjusted Incident Rate (EAIR) of CEC Confirmed Composite Endpoints | LCZ696 | Cardiovascular (CV) Death | 4.410 | 95% Confidence Interval 2.348 to 7.542 | Events per 100 patient-years |
| Exposure-adjusted Incident Rate (EAIR) of CEC Confirmed Composite Endpoints | Enalapril | Cardiovascular (CV) Death | 3.734 | 95% Confidence Interval 1.864 to 6.681 | Events per 100 patient-years |
| Exposure-adjusted Incident Rate (EAIR) of CEC Confirmed Composite Endpoints | LCZ696 | 1st heart failure (HF) Hospitalization | 9.480 | 95% Confidence Interval 6.135 to 13.995 | Events per 100 patient-years |
| Exposure-adjusted Incident Rate (EAIR) of CEC Confirmed Composite Endpoints | Enalapril | 1st heart failure (HF) Hospitalization | 7.498 | 95% Confidence Interval 4.580 to 11.579 | Events per 100 patient-years |
| Key Secondary: Change From Baseline to the Pre-defined Time-points in Log-transformed Concentration of N-terminal Pro-brain Natriuretic Peptide (NT-proBNP) | LCZ696 | Week 4 (n = 111, 110, 0, 0) | 0.7672 | 95% Confidence Interval 0.6988 to 0.8423 | ratio |
| Key Secondary: Change From Baseline to the Pre-defined Time-points in Log-transformed Concentration of N-terminal Pro-brain Natriuretic Peptide (NT-proBNP) | Enalapril | Week 4 (n = 111, 110, 0, 0) | 0.8862 | 95% Confidence Interval 0.8071 to 0.9731 | ratio |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02468232/results